SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as an UBS upgrade sparked bullish sentiment, with the community eyeing a potential short squeeze and significant gains. Traders are closely watching NIO Day and ES8 deliveries, drawing comparisons to other EV manufacturers like Tesla. The stock is facing resistance, but many believe it has the potential to reach much higher prices.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending due to speculation around potential government contracts and recent congressional stock disclosures, fueling retail trader buzz. The community is actively discussing the possibility of a short squeeze and anticipating further gains, with some drawing comparisons to Palantir's growth trajectory. High options volume and increasing interest from institutional investors are adding to the positive sentiment.

Turbo Energy SA provides energy solutions. It engages in the developing, manufacturing and distributing of photovoltaic products. The company was founded on September 18, 2013 and is headquartered in Valencia, Spain.

Turbo Energy S.A. - ADR

Turbo Energy (TURB) is trending due to a significant $53 million contract to deploy solar storage projects, sparking excitement about the company's growth potential in the energy sector. Community discussions revolve around the stock's volatile price action, potential short squeeze opportunities, and comparisons to other high-flying stocks. Some traders are also noting its low float, which may contribute to price swings.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as the company received UK regulatory approval for its acquisition of Oxford Ionics, potentially accelerating its technology roadmap; the community is actively discussing the deal's implications and future catalysts such as the Quantum World Congress. Bullish sentiment is fueled by analyst upgrades, increased price targets, and perceived momentum in the quantum computing sector, while bears question the valuation and long-term profitability.

Lazydays Holdings, Inc. retails recreational vehicles, motorcycles, jet skis and related accessories. The company operates recreation vehicle dealerships, generating revenue by providing RV owners a full spectrum of products: RV sales, RV services, financing and insurance products, RV parts and accessories, RV rentals, third-party protection plans, and RV camping. Lazydays Holdings was founded in 1976 and is headquartered in Tampa, FL.

Lazydays Holdings Inc

Lazydays Holdings ($GORV) is trending due to a recent acquisition announcement and a letter of intent with Campers Inn, including consideration for furniture and equipment. The community is actively discussing the potential impact of this acquisition, with some speculating about a pump and dump, while others are encouraged by the company's book value. Discussions also include the possibility of future offerings and price targets.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as the community discusses its potential inclusion in the S&P 500 and the possibility of acquiring TikTok. Bullish sentiment is fueled by analysts raising price targets and expansion into international markets, while some traders are eyeing a potential pullback from recent highs and expressing concerns about overvaluation and manipulation.

FGI Industries Ltd. engages in the supply of kitchen and bath products. Its products fall under the following categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The Sanitaryware category offers bath products such as toilets, sinks, pedestals and toilet seats. The Bath Furniture category deals with wood and wood-substitute furniture for bathrooms, including vanities, mirrors, laundry and medicine cabinets, and other storage systems. The Shower Systems category includes a range of shower-related products such as shower walls, shower doors and shower basins. The Others category includes shower door and shower systems products, custom kitchen cabinetry, and other accessory items. The company was founded on May 26, 2021 and is headquartered in East Hanover, NJ.

FGI Industries Ltd

FGI is trending due to its low float and potential for a short squeeze, mirroring the recent movements of other low-float stocks. The community is actively discussing its high trading volume relative to its float, with some suggesting it could reach new highs. Several users are pointing to the company's fundamentals, such as cash position and lack of debt, as reasons for potential growth.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense is trending as community members highlight its strength within the defense sector and potential for further gains, with some eyeing triple-digit prices. A catalyst appears to be related to upcoming events and potential news, leading to discussions around its involvement in key defense programs. Investors are actively discussing its valuation, growth prospects, and potential contracts within the broader context of increasing defense spending.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as investors discuss its potential pivot towards HPC/AI, drawing comparisons to other miners already in the space like $IREN and $CIFR. Community members are weighing the company's existing Bitcoin mining operations against opportunities in the AI sector, while also noting a high short interest and potential for a short squeeze. Some traders are monitoring borrowing fees and levels, while others discuss technical indicators and potential price movements related to broader market trends.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is trending amid discussions around recent executive stock sales, a completed acquisition, and revised financial guidance, leading to mixed sentiment. While some investors express frustration over the stock's volatile behavior and perceived mismanagement, others remain bullish, pointing to the company's long-term potential and strategic moves. Community talking points include potential catalysts, market manipulation, and the impact of institutional ownership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy

Annovis Bio Inc.&nbsp;shares saw heightened volatility early Tuesday after the FDA approved the final protocol for its pivotal Phase 3 Alzheimer’s disease (AD) study, grabbing significant attention among retail investors.&nbsp;The revised protocol combines a six-month symptomatic evaluation with a 12-month disease-modifying assessment into a single trial, slated to start in January.In October 2024, Annovis secured FDA clearance to advance its late-stage studies based on promising Phase 2/3 data showing cognitive improvements in early-stage AD patients.&nbsp;According to CEO Maria Maccecchini, the new streamlined design allows for an accelerated timeline while maintaining scientific rigor, potentially enabling a New Drug Application (NDA) filing based on the six-month data while continuing to gather long-term results.On Stocktwits, retail sentiment for Annovis turned ‘extremely bullish,’ driving the ticker to the top of the platform’s trending tab.&nbsp;A bullish user predicted that, in a year, investors would regret not buying Annovis stock at its current price.<stembedurl>https://stocktwits.com/stockpro27/message/599105236</stembedurl>Another speculated there might be some major financing news based on the latest update.<stembedurl>https://stocktwits.com/Pasakorius/message/599096373</stembedurl>As of November 2024, Annovis had $13.6 million in cash, which the company had said was enough to prepare for and enter the Phase 3 study.One analyst earlier&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anvs-stock-jumps-after-analyst-reiterates-buy/cJczO3TRI2">speculated</a> the stock could surge to $30, more than a six-fold jump from current levels, if an NDA is successfully filed.Buntanetap, Annovis’ experimental drug, takes a multi-target approach to address toxic proteins like amyloid, tau, and alpha-synuclein, offering hope as a comprehensive treatment for neurodegenerative diseases, including AD and Parkinson’s.Despite losing 67% of its value in 2024, Annovis’ latest update has reignited investor interest, with analysts suggesting significant upside potential tied to the drug’s success.&nbsp;The company now faces a pivotal year as it advances its mission to develop a groundbreaking treatment for neurodegenerative diseases.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Buntanetap, Annovis’ experimental drug, takes a multi-target approach to address toxic proteins like amyloid, tau, and alpha-synuclein. | Image source: Getty Images 

Annovis Bio Stock Among Retail's Top Draws After FDA Nod For Final Phase 3 Alzheimer’s Study Protocol

According to CEO Maria Maccecchini, the new streamlined design potentially enables a New Drug Application filing based on the six-month data.

Equity

Shares of Annovis Bio, Inc. (<a class="mention" data-mention="$ANVS" data-symbol-id="ANVS" href="https://stocktwits.com/symbol/ANVS" target="_blank">$ANVS</a>) surged more than 17% on Wednesday following an analyst’s reiteration of a ‘Buy’ rating and a $30 price target, which represents an upside of over 200% from current levels.H.C. Wainwright analyst Ram Selvaraju based his bullish outlook on the advancement of Annovis Bio’s lead Alzheimer’s drug candidate, buntanetap.The FDA recently granted clearance for the company to proceed to Phase 3 trials, following successful Phase 2 results that showed improvement in Alzheimer’s patients.The analyst highlighted this regulatory clarity as a critical milestone, adding that the lack of safety concerns around the drug further reduces development risks.Selvaraju also noted that if Annovis successfully files New Drug Applications (NDAs) for buntanetap, it could dramatically increase the company’s valuation. His $30 price target is supported by a discounted cash flow analysis.<figure class="image"><a href="https://stocktwits.com/symbol/ANVS"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ANVS_sentiment_and_message_volume_Oct_16_2024_19c60dcfb9.png" alt="ANVS sentiment and message volume Oct 16 2024.png" width="1314" height="320"></a><figcaption>ANVS sentiment and message volume Oct 16 2024 as of 1:45 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for ANVS remained ‘bullish’ with ‘extremely high’ message volume following the company’s update.<stembedurl>https://stocktwits.com/Cresskill198/message/589126954</stembedurl><stembedurl>https://stocktwits.com/dwayne09/message/589126026</stembedurl>On Tuesday, Annovis announced a successful End-of-Phase 2 meeting with the FDA, aligning both parties on a clear development path for buntanetap.The Phase 3 program will consist of two trials: a 6-month study focusing on symptomatic improvement and an 18-month study aimed at evaluating potential disease-modifying effects.Buntanetap’s multi-target approach seeks to reduce toxic proteins like amyloid, tau, and alpha-synuclein, providing a comprehensive treatment option for neurodegenerative diseases such as Alzheimer’s and Parkinson’s.Still, ANVS stock remains down over 50% this year.Read next: <a href="https://stocktwits.com/news-articles/markets/equity/csco-stock-jumps-after-citi-uprgade/cJczJmJRIR">Cisco Stock Hits 13-Month High After Citi Upgrade: Retail Confidence Grows</a>

On Tuesday, Annovis announced a successful End-of-Phase 2 meeting with the FDA, aligning both parties on a clear development path for buntanetap.

Annovis Bio Stock Surges As Analyst Reiterates ‘Buy’ On Alzheimer’s Drug Progress: Retail Stays Bullish

The FDA recently granted clearance for the company to proceed to Phase 3 trials, following successful Phase 2 results that showed improvement in Alzheimer’s patients.

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More PR Newswire NEW YORK...

<ul><li>Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma</li><li>Small Biotech Companies Lead the Charge with Disruptive Approaches to Treating Alzheimer’s</li></ul>Alzheimer’s disease has been one of the most challenging conditions for the pharmaceutical industry to address. While companies like&nbsp;Biogen (BIIB) and&nbsp;Eli Lilly (LLY) have made notable strides with drugs like&nbsp;Aduhelm and&nbsp;Donanemab, which target amyloid plaques, breakthrough treatments that offer substantial cognitive improvements remain elusive. Despite these advancements, many of these drugs focus on slowing disease progression rather than providing a cure, and their impact has been limited.Historically, much of the innovation in Alzheimer’s research has come from smaller biotech companies, many of which are eventually acquired by larger pharmaceutical firms like BIIB and LLY. However, the results from these acquisitions have often not met expectations, leaving room for new players to disrupt the market with more innovative approaches.For investors looking for broader exposure to the biotech sector, the&nbsp;XBI ETF (SPDR S&amp;P Biotech ETF) offers a more diversified way to play the space. XBI tracks an equal-weighted index of U.S. biotech stocks, providing exposure to both large players like Biogen and smaller upstarts working on novel treatments. The ETF has seen strong performance recently, driven by optimism around biotech innovation in areas like Alzheimer’s, oncology, and rare diseases. While individual biotech stocks can be volatile, XBI spreads the risk across a broader portfolio, making it a compelling option for those looking to invest in the sector without taking on the higher risk of single-stock picks.The Alzheimer’s drug market is projected to reach $13.7 billion by 2029, and despite the presence of big pharma, there remains a significant opportunity for companies with novel therapies to address this unmet need. In this article, we examine three small-cap biotech players —&nbsp;Cassava Sciences (SAVA),&nbsp;INmune Bio (INMB), and&nbsp;Annovis Bio (ANVS) — that are working on breakthrough Alzheimer’s therapies. We will break down their potential by analyzing the good, the bad, the ugly, and their overall investability.&nbsp;<h4>Read Now:&nbsp;<a href="https://wealthyvc.com/featured/20m-healthcare-stock-breaks-out-after-rising-1700-on-medicare-and-medicaid-clearance-heres-whats-being-announced-in-the-coming-months-in-a-25x-larger-market/">This $20m Company Soars 1,700% on Medicare &amp; Medicaid Clearance— Find out What’s Being Announced in the Coming Months in a Market 25X Larger</a></h4>&nbsp;<h3>Cassava Sciences (SAVA)&nbsp;<a href="https://stocktwits.com/symbol/SAVA">[Follow on Stocktwits.com]</a></h3><h4>The Lowdown:</h4>Cassava Sciences is developing Simufilam, a drug that targets a unique protein misfolding pathway in Alzheimer’s disease. Unlike traditional therapies that focus solely on amyloid plaques, Simufilam aims to correct the shape of the protein Filamin A, which may influence multiple Alzheimer’s disease processes. This innovative approach could potentially address multiple aspects of the disease.Cassava has faced a mix of positive and negative news. Its Phase 2 trial results showed cognitive improvement in Alzheimer’s patients, generating optimism. However, allegations of data manipulation have cast a cloud over the company’s achievements, leading to regulatory scrutiny and volatility in the stock.<h4>The Good:</h4>Simufilam’s unique approach could disrupt the Alzheimer’s drug market if Phase 3 trials confirm its efficacy. With Alzheimer’s treatments falling short of significant impact, a drug that improves cognitive function would undoubtedly capture massive attention. Additionally, Cassava’s high short interest could lead to a short squeeze if positive news emerges, providing an opportunity for investors to capitalize on sharp price movements. Notably, if the drug succeeds, the company’s stock could skyrocket, presenting massive upside potential for investors.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_03_at_11_27_24_AM_67dc564cb2.png" alt="Screenshot 2024-10-03 at 11.27.24 AM.png"><h4>The Bad:</h4>The allegations of data manipulation have raised questions about the integrity of Cassava’s research. Although the company has denied wrongdoing, the concerns could weigh heavily on investor confidence until the Phase 3 data is released. Moreover, Alzheimer’s disease is notoriously difficult to treat, and even promising drugs can fail in late-stage trials.<h4>The Ugly:</h4>Cassava’s main challenge is that it’s a one-trick pony. The company’s future is almost entirely dependent on the success of Simufilam. If the Phase 3 trials show negative results, the stock could plummet, potentially wiping out investors. Cassava lacks diversification in its pipeline, and failure could be disastrous for the company’s long-term viability.<h4>Investability:</h4>Cassava Sciences is a high-risk, high-reward stock. For investors willing to take on significant risk, the potential upside of Simufilam is enormous. However, given the controversies surrounding the company, a cautious approach is warranted. Those looking for long-term gains should monitor the Phase 3 results closely before making any major investments.&nbsp;<h3>INmune Bio (INMB)&nbsp; <a href="https://stocktwits.com/symbol/inmb">[Follow on Stocktwits.com]</a></h3><h4>The Lowdown:</h4>INmune Bio is taking a unique approach to treating Alzheimer’s by focusing on neuroinflammation rather than the traditional amyloid or tau pathways. The company’s lead drug, XPro1595, is designed to reduce brain inflammation by neutralizing soluble TNF (sTNF), a cytokine that drives chronic inflammation in Alzheimer’s patients. This could potentially offer a complementary treatment to existing therapies. In addition to its Alzheimer’s focus, INmune Bio has a strong oncology portfolio, which includes its INKmune platform aimed at improving cancer immunotherapy.Recent clinical data on XPro1595 has been promising, with the drug showing efficacy in reducing neuroinflammation. The company is preparing for larger trials in 2025, which could solidify its position in the Alzheimer’s space.<h4>The Good:</h4>INmune Bio’s focus on neuroinflammation sets it apart from other Alzheimer’s treatments. Reducing inflammation has shown to be a crucial factor in preventing cognitive decline, and XPro1595’s early data suggests it could be a game-changer in this area. Furthermore, INmune Bio’s diversified portfolio, including its oncology platform, gives it additional avenues for growth beyond Alzheimer’s, reducing its risk compared to Cassava Sciences.<h4>The Bad:</h4>Despite the promise of XPro1595, the drug is still in early-stage trials, and it could take years before it reaches the market. The road to FDA approval is long and fraught with challenges, and investors will need to be patient as the company moves through its clinical development phases.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_03_at_11_28_27_AM_bf6e45fe54.png" alt="Screenshot 2024-10-03 at 11.28.27 AM.png"><h4>The Ugly:</h4>One of the biggest risks for INmune Bio is its reliance on early-stage data. While XPro1595 has shown promise, it has not yet demonstrated long-term efficacy in larger trials. Any setbacks in the trial process could delay the drug’s development and hurt the company’s stock.<h4>Investability:</h4>INmune Bio offers the best reward-to-risk ratio among the three companies. With a diversified portfolio and a promising Alzheimer’s treatment, INmune Bio is well-positioned to capitalize on breakthroughs in both neuroinflammation and oncology. Investors looking for a biotech stock with high upside potential but less concentrated risk compared to Cassava Sciences may find INmune Bio to be a compelling option.<h4>Read Now:&nbsp;<a href="https://wealthyvc.com/featured/20m-healthcare-stock-breaks-out-after-rising-1700-on-medicare-and-medicaid-clearance-heres-whats-being-announced-in-the-coming-months-in-a-25x-larger-market/">This $20m Company Soars 1,700% on Medicare &amp; Medicaid Clearance— Find out What’s Being Announced in the Coming Months in a Market 25X Larger</a></h4>&nbsp;<h3>Annovis Bio (ANVS)&nbsp;&nbsp;<a href="https://stocktwits.com/symbol/ANVS">[Follow on Stocktwits.com]</a></h3><h4>The Lowdown:</h4>Annovis Bio is targeting Alzheimer’s with Buntanetap, a drug that aims to reduce multiple neurotoxic proteins, including amyloid, tau, and alpha-synuclein. By taking a multi-pronged approach, Annovis hopes to provide a more comprehensive treatment for neurodegenerative diseases like Alzheimer’s and Parkinson’s.The company recently reported positive early-stage trial results, showing that Buntanetap improved cognition in patients with Alzheimer’s. With a Phase 2 trial in progress, Annovis Bio is positioning itself as a serious contender in the Alzheimer’s space.<h4>The Good:</h4>Buntanetap’s ability to target multiple neurotoxic proteins gives it an advantage over single-target therapies. The early data showing cognitive improvement has bolstered investor confidence, and the drug’s potential to address both Alzheimer’s and Parkinson’s opens up additional market opportunities. If Buntanetap continues to perform well in clinical trials, Annovis Bio could see substantial growth.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_03_at_11_29_39_AM_fafa150775.png" alt="Screenshot 2024-10-03 at 11.29.39 AM.png"><h4>The Bad:</h4>However, Annovis Bio is still in the early stages of its clinical trials, and the road to commercialization is long. The company will need to demonstrate consistent efficacy in larger trials before it can become a serious player in the Alzheimer’s market. Additionally, competition from other multi-target therapies could limit its market share.<h4>The Ugly:</h4>Like many small biotech companies, Annovis Bio is reliant on the success of a single drug candidate. If Buntanetap fails in its clinical trials, the company could struggle to recover. Investors should be aware of the high risk associated with this stock.<h4>Investability:</h4>Annovis Bio presents a speculative but potentially rewarding investment. The company’s multi-target approach could offer greater efficacy than traditional Alzheimer’s treatments, but it remains a high-risk bet. Investors should monitor the progress of its clinical trials closely before making any significant investments.<h3>Conclusion</h3>The Alzheimer’s drug market is poised for disruption, and companies like Cassava Sciences, INmune Bio, and Annovis Bio are leading the charge with innovative treatments. While these stocks come with substantial risks, the potential rewards could be life-changing — both for patients and investors. For those willing to take a gamble on the future of Alzheimer’s treatment, these companies offer a unique opportunity to not only achieve significant financial gains but also to contribute to a cause that could improve millions of lives.Of the three, INmune Bio stands out for its diversified portfolio and promising early data, making it a potentially safer bet. Cassava Sciences offers the most dramatic upside but comes with higher risks due to its single-drug focus. Annovis Bio, while speculative, offers intriguing potential with its multi-targeted approach.As always, investors should weigh the risks and rewards carefully but know that their investments could make a profound difference in the fight against one of the most challenging diseases of our time.&nbsp;<h4>Read Now:&nbsp;<a href="https://wealthyvc.com/featured/20m-healthcare-stock-breaks-out-after-rising-1700-on-medicare-and-medicaid-clearance-heres-whats-being-announced-in-the-coming-months-in-a-25x-larger-market/">This $20m Company Soars 1,700% on Medicare &amp; Medicaid Clearance— Find out What’s Being Announced in the Coming Months in a Market 25X Larger</a></h4>&nbsp;This author or the principals of WVC do not hold any of the stocks mentioned in this article.&nbsp;<ul><li><a href="http://www.stocktwits.com/wealthyvc">Follow us on Stocktwits</a>&nbsp;</li><li><a href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a></li><li>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at&nbsp;Invest@WealthyVC.com</li></ul>

Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market

Discover how small-cap biotech companies like Cassava Sciences, INmune Bio, and Annovis Bio are shaking up the $13.7 billion Alzheimer’s drug market with innovative treatments. Explore their potential for high-risk, high-reward gains

Small biotech firms like Cassava Sciences, INmune Bio, and Annovis Bio are developing innovative Alzheimer’s treatments, disrupting big pharma’s dominance in the $13.7B market. For those targeting groundbreaking therapies, high-risk, high-reward investments lie ahead.


Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition

Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition PR Newswire NEW YORK, Oct. 1, 2024...

Annovis Bio Raises $7 Million from Warrant Exercises

An update from Annovis Bio (ANVS) is now available. Annovis Bio, Inc. has successfully exercised 0.8 million warrants issued in November 2023, resu...

Maxim Group Sticks to Its Hold Rating for Annovis Bio (ANVS)

Maxim Group analyst Jason McCarthy maintained a Hold rating on Annovis Bio (ANVS Research Report) yesterday. The company's shares opened today at...

Peering Into Annovis Bio's Recent Short Interest

What's Going On With Annovis Shares Today?

Annovis Bio shares rise in premarket trading on positive Phase III Parkinson's study results for buntanetap, showing cognitive improvements and stability compared to placebo.
read more...

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. The company's product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. Annovis Bio was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

Annovis Bio Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

Current Price	$2.40
Prev Close	$2.39
Open	$2.37
Dividend Yield	0.00%
50-Day Moving Average	$2.57
Beta	1.36
Avg. Volume	242,543.10
PE Ratio	-1.14

52-Week High	$10.54
52-Week Low	$1.11
Market Capitalization	$46.57M
EPS (Annual)	-$2.31
Price to Book	2.54
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ANVS
Annovis Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANVS News

ANVS Annovis Bio Inc